Related Experiment Video
Updated: May 3, 2026
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass
Latif Rachdi1, Dulanjalee Kariyawasam, Fanny Guez
1INSERM U1016, Institut Cochin, Faculté de Médecine Cochin, Université Paris Descartes, 24 Rue du Faubourg St Jacques, 75014, Paris, France, latif.rachdi@inserm.fr.
Aims/Hypothesis:
Growth factors and nutrients are important regulators of pancreatic beta cell mass and function. However, the signalling pathways by which these factors modulate these processes have not yet been fully elucidated. DYRK1A (also named minibrain/MNB) is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family that has been conserved across evolution. A significant amount of data implicates DYRK1A in brain growth and function, as well as in neurodegenerative processes in Alzheimer's disease and Down's syndrome. We investigated here whether DYRK1A would be an attractive candidate for beta cell growth modulation.
Methods:
To study the role of DYRK1A in beta cell growth, we used Dyrk1a-deficient mice.
Results:
We show that DYRK1A is expressed in pancreatic islets and provide evidence that changes in Dyrk1a gene dosage in mice strongly modulate glycaemia and circulating insulin levels. Specifically, Dyrk1a-haploinsufficient mice show severe glucose intolerance, reduced beta cell mass and decreased beta cell proliferation.
Conclusions/Interpretation:
Taken together, our data indicate that DYRK1A is a critical kinase for beta cell growth as Dyrk1a-haploinsufficient mice show a diabetic profile.
Insights
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is crucial for pancreatic beta cell growth. Reduced DYRK1A levels in mice lead to glucose intolerance and a diabetic profile, highlighting its role in regulating beta cell mass and function.
Area of Science:
- Endocrinology
- Molecular Biology
- Genetics
Background:
- Pancreatic beta cell mass and function are regulated by growth factors and nutrients.
- Signaling pathways controlling beta cell mass are not fully understood.
- DYRK1A, a conserved kinase, is implicated in brain development and neurodegenerative diseases.
Purpose of the Study:
- To investigate the role of DYRK1A in modulating pancreatic beta cell growth.
- To determine if DYRK1A is a potential therapeutic target for diabetes.
Main Methods:
- Utilized Dyrk1a-deficient mouse models to study DYRK1A function.
- Analyzed glycaemia, circulating insulin levels, beta cell mass, and proliferation.
Main Results:
- DYRK1A is expressed in pancreatic islets.
- Altered Dyrk1a gene dosage significantly impacts glycaemia and insulin levels in mice.
- Dyrk1a-haploinsufficient mice exhibit severe glucose intolerance, reduced beta cell mass, and decreased beta cell proliferation.
Conclusions:
- DYRK1A is a critical kinase essential for pancreatic beta cell growth.
- DYRK1A deficiency in mice results in a diabetic phenotype, underscoring its importance in maintaining glucose homeostasis.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
01:12Type I Diabetes I: Introduction
01:24Type II Diabetes II: Pathophysiology
01:26Type II Diabetes I: Introduction
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...